Fernández Agra, MaríaGonzález Serrano, JoséPedro Herráez, Miguel deVirto Ruiz, LeireCaponio, Vito Carlo AlbertoIbáñez Prieto, ElenaHernández Vallejo, GonzaloLópez-Pintor Muñoz, Rosa María2023-06-222023-06-222022-09-221601-082510.1111/odi.14390https://hdl.handle.net/20.500.14352/72124CRUE-CSIC (Acuerdos Transformativos 2022)The objective of this systematic review was to evaluate which salivary biomarkers are altered in patients with burning mouth syndrome (BMS) compared to a control group (CG). A comprehensive literature search was conducted in four databases. Case– control studies evaluating salivary biomarkers in BMS patients were included. Risk of bias was assessed using the Newcastle-Ottawa tool. RevMan was used for metaanalysis. Seventeen studies were selected. The included studies collected 54 different biomarkers. Of these biomarkers, only three (cortisol, α-amylase, and dehydroepiandrosterone) were analyzed in three or more studies. Dehydroepiandrosterone obtained contradictory results among the studies. However, cortisol and α-amylase levels were found to be higher in BMS patients. Cortisol was the only biomarker which could be included for meta-analysis. Cortisol levels were significantly higher in the BMS group compared to the CG (Mean Difference = 0.39; 95% CI [0.14–0.65]; p = 0.003). In conclusion, different studies investigated salivary biomarkers in patients with BMS compared to a CG, with controversial results. Meta-analysis, confirmed by trial-sequential analysis, showed how cortisol levels were significantly higher in BMS. Cortisol emerges as an interesting salivary biomarker in BMS, but future properly designed studies are needed to evaluate its role in diagnosis and/or response to treatment.engAtribución-NoComercial-SinDerivadas 3.0 Españajournal articlehttps://doi.org/10.1111/odi.14390open accessbiomarkersburning mouth syndromesalivasalivary biomarkersOdontología (Odontología)3213.13 Ortodoncia-Estomatología